l-asparaginase resistance in human leukemia--asparagine synthetase.

No abstract is available for this paper.

• Publication year

  1969

• Venue

  Biochemical Pharmacology

• Publication date

  1969-10-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/0006-2952(69)90375-XPMID 4935103
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Statistics: An Intuitive Approach

  1971cited by this paper
• STUDIES ON THE MECHANISM OF TUMOR INHIBITION BY L-ASPARAGINASE

  1968cited by this paper
• Asparagine synthetase in asparaginase resistant and susceptible mouse lymphomas.

  1968cited by this paper
• Asparagine biosynthesis by the Novikoff Hepatoma isolation, purification, property, and mechanism studies of the enzyme system.

  1968cited by this paper
• Asparagine synthetase in normal and malignant tissues: correlation with tumor sensitivity to asparaginase.

  1968cited by this paper
• Asparagine Synthetase Activity of Mouse Leukemias

  1968cited by this paper
• L-asparagine biosynthesis by nutritional variants of the Jensen sarcoma.

  1967cited by this paper
• Differences in the production of L-asparagine in asparaginase-sensitive and resistant lymphoma cells.

  1967cited by this paper
• ALTERATIONS IN PROTEIN AND NUCLEIC ACID METABOLISM OF LYMPHOMA 6C3HED-OG CELLS IN MICE GIVEN GUINEA PIG SERUM

  1966cited by this paper
• A Metabolic Difference Between Two Lines of Lymphoma 6C3HED Cells in Relation to Asparagine.∗

  1965cited by this paper
• EVIDENCE THAT THE L-ASPARAGINASE OF GUINEA PIG SERUM IS RESPONSIBLE FOR ITS ANTILYMPHOMA EFFECTS

  1963cited by this paper
• [83A] Determination of aspartic acid and asparagine

  1957cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Structural Features Underlying the Mismatch Between Catalytic and Cytostatic Properties in L-Asparaginase from Rhodospirillum rubrum

  2025cites this paper
• Asparagine Dependency is a Targetable Metabolic Vulnerability in TP53-Altered Castration-Resistant Prostate Cancer.

  2024cites this paper
• Identifying targetable metabolic dependencies across colorectal cancer progression

  2023cites this paper
• Biochemical Markers of Tumor Cell Sensitivity to L-Asparaginase

  2023cites this paper
• Metabolism in Hematopoiesis and Its Malignancy.

  2023cites this paper
• Development of a bioengineered Erwinia chrysanthemi asparaginase to enhance its anti-solid tumor potential for treating gastric cancer.

  2023cites this paper
• Arginine-depleting Enzymes, A Potential Treatment Option for Tumors With Arginine Auxotrophy : A Review

  2023cites this paper
• Possible mechanism of metabolic and drug resistance with L-asparaginase therapy in childhood leukaemia

  2023cites this paper
• PEG-asparaginase treatment regimens for acute lymphoblastic leukaemia in children: a network meta-analysis.

  2023cites this paper
• Amino acids in hematologic malignancies: Current status and future perspective

  2023cites this paper
• Polyoxazoline-Conjugated l-Asparaginase: An Antibody-Production-Free Therapeutic Agent for Acute Lymphoblastic Leukemia.

  2023cites this paper
• Changes in serum amino acid levels in non-small cell lung cancer: a case-control study in Chinese population

  2022cites this paper
• Mechanisms of Development of Side Effects and Drug Resistance to Asparaginase and Ways to Overcome Them

  2022cites this paper
• Novel Insights on the Use of L-Asparaginase as an Efficient and Safe Anti-Cancer Therapy

  2022cites this paper
• Predictive markers for efficiency of the amino-acid deprivation therapies in cancer

  2022cites this paper
• Supramolecular assembly of GSK3α as a cellular response to amino acid starvation.

  2022cites this paper
• Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells

  2021cites this paper
• Pharmacologic approaches to amino acid depletion for cancer therapy

  2021influential citation
• Insights on Metabolic Reprogramming and Its Therapeutic Potential in Acute Leukemia

  2021cites this paper
• PEG-asparaginase treatment for acute lymphoblastic leukaemia in children: a network meta-analysis

  2021cites this paper
• Asparagine Synthetase in Cancer: Beyond Acute Lymphoblastic Leukemia

  2020cites this paper
• Epigenetic Silencing Affects l-Asparaginase Sensitivity and Predicts Outcome in T-ALL

  2019cites this paper
• Insights into the Microbial L-Asparaginases: from Production to Practical Applications.

  2019cites this paper
• Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias

  2019cites this paper
• Amino Acid Metabolism in Hematologic Malignancies and the Era of Targeted Therapy.

  2019cites this paper
• Metabolism within the tumor microenvironment and its implication on cancer progression: An ongoing therapeutic target

  2019cites this paper
• HAP1 loss confers l-asparaginase resistance in ALL by downregulating the calpain-1-Bid-caspase-3/12 pathway.

  2019cites this paper
• Targeting extracellular nutrient dependencies of cancer cells

  2019cites this paper
• Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response

  2018cites this paper
• Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias

  2018cites this paper
• L-Asparaginase Related Thrombotic Complications in Acute Lymphoblastic Leukemia Patients – An Experience from a Tertiary Care Centre

  2018cites this paper
• Metabolic underpinnings of leukemia pathology and treatment

  2018cites this paper
• Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia

  2018cites this paper
• Genetic predisposition to PEG‐asparaginase hypersensitivity in children treated according to NOPHO ALL2008

  2018cites this paper
• Comparison of hypersensitivity rates to intravenous and intramuscular PEG‐asparaginase in children with acute lymphoblastic leukemia: A meta‐analysis and systematic review

  2017cites this paper
• Catalyzing improvements in ALL therapy with asparaginase.

  2017cites this paper
• Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia

  2017cites this paper
• Drug-induced amino acid deprivation as strategy for cancer therapy

  2017cites this paper
• Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia.

  2016cites this paper
• Asymmetrical flow field-flow fractionation for the analysis of PEG-asparaginase.

  2016cites this paper
• [Expression of asparagine synthetase in relapsed or refractory extranodal NK/T cell lymphoma].

  2016cites this paper
• Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study

  2016cites this paper
• Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines

  2015cites this paper
• ALERGIJSKA REAKCIJA NA L - ASPARAGINAZU I ISHOD LIJEČENJA AKUTNE LIMFOBLASTIČNE LEUKEMIJE KOD DJECE

  2015cites this paper
• Effectiveness of premedication and rapid desensitization in hypersensitivity to L-asparaginase

  2015cites this paper
• Clinical analysis and prognostic significance of L-asparaginase containing multidrug chemotherapy regimen in incipient peripheral T-cell lymphoma.

  2015cites this paper
• Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: A Focus on the Mode of Drug Resistance.

  2015cites this paper
• Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase

  2014cites this paper
• Crystal structure of active site mutant of antileukemic l‐asparaginase reveals conserved zinc‐binding site

  2014cites this paper
• Asparagine Synthetase Polymorphisms and Toxicity and Efficacy of Asparaginases

  2014cites this paper
• activity against ASNS-negative cells The glutaminase activity of l-asparaginase is not required for anticancer

  2014cites this paper
• Comparison of Allergic Reactions to Intravenous and Intramuscular Pegaspargase in Children with Acute Lymphoblastic Leukemia

  2014cites this paper
• Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion.

  2014cites this paper
• Important Sources and Medicinal Applications of L-Asparaginase

  2014cites this paper
• Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia.

  2013cites this paper
• Pharmacogenomic approaches for tailored anti-leukemic therapy in children.

  2013cites this paper
• Leukemia-bearing Mice -d-Arabinofuranosylcytosine and 5-Fluorouracil in L1210 β Histidinol-mediated Improvement in the Specificity of 1-

  2013cites this paper
• Towards a metabolic therapy of cancer?

  2013cites this paper
• Biology – cancer metabolic phenotype

  2013cites this paper
• XVI CICLO DEL DOTTORATO DI RICERCA IN

  2013cites this paper
• Preserving catalytic activity and enhancing biochemical stability of the therapeutic enzyme asparaginase by biocompatible multilayered polyelectrolyte microcapsules.

  2013cites this paper
• The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells.

  2013cites this paper
• Erwinia asparaginase in pediatric acute lymphoblastic leukemia

  2012cites this paper
• Targeting the latest hallmark of cancer: another attempt at 'magic bullet' drugs targeting cancers' metabolic phenotype.

  2012cites this paper
• Cancer cell metabolism: one hallmark, many faces.

  2012cites this paper
• Asparagine and aspartic acid concentrations in bone marrow versus peripheral blood during Berlin–Frankfurt–Münster-based induction therapy for childhood acute lymphoblastic leukemia

  2012cites this paper
• Microbial L-Asparaginase and its future prospects

  2012cites this paper
• A sulfoximine-based inhibitor of human asparagine synthetase kills L-asparaginase-resistant leukemia cells.

  2012cites this paper
• Low expression of asparagine synthetase in lymphoid blasts precludes its role in sensitivity to L-asparaginase.

  2012cites this paper
• Bacterial Asparaginase: A Potential Antineoplastic Agent for Treatment of Acute Lymphoblastic Leukemia

  2012cites this paper
• Genomics and cancer drug resistance.

  2012cites this paper
• Engineering reduced-immunogenicity enzymes for amino acid depletion therapy in cancer.

  2012cites this paper
• Asparagine Synthetase Is Partially Localized to the Plasma Membrane and Upregulated by L-asparaginase in U 937 Cells *

  2011cites this paper
• A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity

  2011cites this paper
• Exploration of soil and marine sources for Microbes producing Asparaginase

  2011cites this paper
• Asparagine synthetase is partially localized to the plasma membrane and upregulated by L-asparaginase in U937 cells

  2011cites this paper
• Alternatives thérapeutiques à la L-asparaginase native dans le traitement de la leucémie aiguë lymphoblastique de l'adulte

  2010cites this paper
• Tolerability and Efficacy of L-Asparaginase Therapy in Pediatric Patients With Acute Lymphoblastic Leukemia

  2010cites this paper
• Genetic Variations in GRIA1 on Chromosome 5q33 Related to Asparaginase Hypersensitivity

  2010cites this paper
• Targeting metabolic transformation for cancer therapy

  2010cites this paper
• Inhibition, characterization, and crystallization of glutamine-dependent asparagine synthetase

  2010cites this paper
• Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia.

  2009cites this paper
• Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase‐associated pancreatitis

  2009cites this paper
• Effect of L-Asparaginase Combined with Vincristine and Prednisolone on Acute Myeloblastic Leukemia (M0) Associated with Non-Hodgkin Lymphoma

  2009cites this paper
• Pegasparaginase: where do we stand?

  2009influential citation
• First-line treatment of acute lymphoblastic leukemia with pegasparaginase riccardo

  2009cites this paper
• A critical electrostatic interaction mediates inhibitor recognition by human asparagine synthetase.

  2009cites this paper
• Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines

  2008cites this paper
• Mass spectrometric quantification of asparagine synthetase in circulating leukemia cells from acute lymphoblastic leukemia patients.

  2008cites this paper
• Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia?

  2008cites this paper
• Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia.

  2007cites this paper
• Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase.

  2007cites this paper
• INTRAMOLECULAR TUNNEL AND REGULATORY MECHANISMS OF ASPARAGINE SYNTHETASE (ASNS)

  2007cites this paper
• Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia.

  2007cites this paper
• Amino Acid Requirements in Vitro of Human Leukemie Cells 1

  2006cites this paper
• An inhibitor of human asparagine synthetase suppresses proliferation of an L-asparaginase-resistant leukemia cell line.

  2006cites this paper
• L-Asparaginase: A Review

  2006cites this paper
• Amino Acid Requirements in Vitro of Human Leukemie Cells1

  2006cites this paper
• Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia.

  2006cites this paper
• UPREGULATION OF ASPARAGINE SYNTHETASE EXPRESSION IS NOT LINKED TO THE CLINICAL RESPONSE TO L-ASPARAGINASE IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA

  2006cites this paper